Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Vibrato Aspiration System - Simple, Intuitive Approach to Clot Removal in Acute Pulmonary Embolism - a Safety & Feasibility Study

23 augusti 2026 uppdaterad av: Vicora, Inc.
The study is a prospective, single-arm, multicenter study to evaluate the safety and effectiveness of the Vibrato™ Aspiration System for aspiration mechanical thrombectomy in the treatment of acute PE. This is the First in Man clinical study.

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Detaljerad beskrivning

The study objective is to evaluate the safety and effectiveness of the Vibrato™ Aspiration System Aspiration System (hereafter referred to as Vibrato™ Aspiration System) for aspiration mechanical thrombectomy in the treatment of acute PE.

The Vibrato™ Aspiration System is a vibration-assisted aspiration thrombectomy device including attributes designed to improve trackability, maintain a low-profile configuration, and operate without capital equipment. In addition, the Vibrato™ Aspiration System features a novel vibrating distal tip designed to enhance thrombus removal during aspiration while minimizing vascular injury. The vibrating mechanism may reduce procedure times, improve clot removal efficiency, and decrease the need for adjunctive interventions.

Studietyp

Interventionell

Inskrivning (Beräknad)

10

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Greater Poland Voivodeship
      • Poznan, Greater Poland Voivodeship, Polen, 61-848
        • Har inte rekryterat ännu
        • Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu Uniwersytecki Szpital Kliniczny
        • Huvudutredare:
          • Aleksander Araszkiewicz, Professor, MD, PhD
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, Polen, 31-202
        • Rekrytering
        • Krakowski Szpital Specjalistyczny im. św. Jana Pawła II
        • Huvudutredare:
          • Grzegorz Kopeć, Professor, MD, PhD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

Subjects must meet all following general inclusion criteria:

  1. Age ≥ 18 and ≤ 75 years.
  2. Clinical signs, symptoms, and presentation consistent with acute PE;
  3. PE symptom duration ≤ 14 days;
  4. CTA evidence (site determined) of proximal PE (filling defect in at least one main or interlobar pulmonary artery)
  5. RV/LV ratio of ≥ 0.9 on CTA as assessed by investigator (site determined).
  6. Systolic blood pressure ≥ 90 mmHg;
  7. Stable heart rate < 130 BPM prior to procedure;
  8. Patient is deemed medically eligible for interventional procedure(s), per institutional guidelines and clinical judgment
  9. Informed Consent Form signed
  10. Subject is willing and able to comply with all Clinical Investigation Plan required follow-up visit

Exclusion Criteria:

Subjects must not meet any of the following general exclusion criteria:

  1. Thrombolytic use within 30 days of baseline CT angiogram
  2. Pulmonary hypertension with peak pulmonary artery pressure > 70 mmHg by right heart catheterization (site determined)
  3. Vasopressor requirement after fluids to keep pressure ≥ 90 mmHg;
  4. FiO2 requirement > 40% or > 6 LPM to keep oxygen saturation > 90%;
  5. Hematocrit < 28%;
  6. Platelets < 100,000/ML;
  7. Serum creatinine > 1.8 mg/dL;
  8. International normalized ratio (INR) > 3;
  9. Major trauma injury severity score (ISS) > 15 within the past 14 days
  10. Presence of intracardiac lead in the right ventricle or right atrium placed within 6 months, Pacemaker or Implantable Cardioverter Defibrillators;
  11. Cardiovascular or pulmonary surgery within last 7 days;
  12. Actively progressing cancer requiring chemotherapy
  13. Known bleeding diathesis or coagulation disorder;
  14. Left bundle branch block;
  15. History of severe or chronic pulmonary arterial hypertension;
  16. History of chronic left heart disease with left ventricular ejection fraction ≤ 30%;
  17. History of uncompensated heart failure;
  18. History of underlying lung disease that is oxygen dependent;
  19. History of chest irradiation;
  20. History of heparin-induced thrombocytopenia (HIT);
  21. Patients who are under intubation
  22. Any contraindication to systemic or therapeutic doses of heparin or anticoagulants;
  23. Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated;
  24. Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for mechanical thrombectomy intervention;
  25. Life expectancy of < 90 days, as determined by Investigator;
  26. Female who is pregnant or nursing;
  27. Current participation in another investigational drug or device treatment study
  28. History of Hemorrhagic or Ischemic Stroke, including Transient Ischemic Attack, within last 90 days
  29. Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Enhetens genomförbarhet
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Single arm study
Vibrato™ Aspiration System for aspiration mechanical thrombectomy in the treatment of acute pulmonary embolism.
Mechanical Thrombectomy for the treatment of Acute Pulmonary Embolism

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Safety Endpoint: Major Adverse Events
Tidsram: 48 hours

Major Adverse Events, a composite of:

  • Device-related death within 48 hours
  • Major bleeding within 48 hours
  • Device-related AEs within 48 hours, including:
  • Clinical deterioration
  • Pulmonary vascular injury
  • Cardiac injury
48 hours
Efficacy Endpoint: Reduction in RV/LV Ratio
Tidsram: 48 hours
Reduction in RV/LV ratio from baseline to 48 hours or discharge by CT angiography
48 hours

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Safety Endpoint: Device-Related Death
Tidsram: 48 hours
Device-related death within 48 hours
48 hours
Safety Endpoint: Major Bleeding
Tidsram: 48 Hours
Major bleeding within 48 hours
48 Hours
Safety Endpoint: Device-Related Clinical Deterioration
Tidsram: 48 Hours
Device-related clinical deterioration within 48 hours
48 Hours
Safety Endpoint: Device-Related Pulmonary Vascular Injury
Tidsram: 48 Hours
Device-related pulmonary vascular injury within 48 hours
48 Hours
Safety Endpoint: Cardiac Injury
Tidsram: 48 Hours
Cardiac injury within 48 hours
48 Hours
Safety Endpoint: Any-Cause Mortality
Tidsram: 30 Days
Any-cause mortality within 30 days
30 Days
Safety Endpoint: Device-Related Serious Adverse Event
Tidsram: 30 Days
Device-related Serious Adverse Events (SAEs) within 30 days
30 Days
Safety Endpoint: Symptomatic Recurrence of Pulmonary Embolism
Tidsram: 30 Days
Symptomatic recurrence of Pulmonary Embolism (PE) within 30 days
30 Days
Efficacy Endpoint: Modified Miller Index Score
Tidsram: 48 Hours
Change in modified Miller Index Score (MMIS) between baseline and 48 hours post-procedure as assessed by CTA
48 Hours
Efficacy Endpoint: Change in Mean Pulmonary Artery Pressure
Tidsram: Procedure
Change in mean pulmonary artery pressure measured invasively in the central pulmonary arteries before vs. after the endovascular procedure [measured in mmHg]
Procedure
Efficacy Endpoint: Procedural Change in Cardiac Index
Tidsram: Procedure
Procedural change in cardiac index [measured in L/min/m^2]
Procedure
Efficacy Endpoint: Length of ICU Stay, Associated with Index Procedure
Tidsram: 30 Days
Length of stay in the ICU associated with the index procedure [measured in days]
30 Days
Efficacy Endpoint: Length of Total Hospital Stay
Tidsram: 30 Days
Length of total hospital stay [measured in days]
30 Days
Efficacy Endpoint: Post-Index Procedure Hospital Length of Stay
Tidsram: 30 Days
Post-index-procedure hospital length of stay [measured in days]
30 Days
Efficacy Endpoint: Procedural Reduction in Pulmonary Artery Mean Pressure
Tidsram: Procedure
Procedural reduction in pulmonary artery mean pressure [measured in mmHg]
Procedure
Efficacy Endpoint: Procedural Reduction in Pulmonary Artery Systolic Pressure
Tidsram: Procedure
Procedural reduction in pulmonary artery systolic pressure [measured in mmHg]
Procedure
Efficacy Endpoint: Reduction in Total Pulmonary Vascular Resistance
Tidsram: Procedure
Procedural reduction in total pulmonary vascular resistance [measured in mmHg ⋅ min/L]
Procedure
Efficacy Endpoint: Change from Baseline in Dyspnea Severity by mMRC Score
Tidsram: 48 Hours
Change from baseline in Dyspnea severity by mMRC score at the 48-hour visit
48 Hours
Efficacy Endpoint: Change from Baseline in Dyspnea Severity by mMRC Score
Tidsram: 30 Days
Change from baseline in Dyspnea severity by mMRC score [Time Frame: at the 30 days visit]
30 Days

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Samarbetspartners

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

21 augusti 2026

Primärt slutförande (Beräknad)

1 oktober 2026

Avslutad studie (Beräknad)

1 december 2026

Studieregistreringsdatum

Först inskickad

18 juni 2026

Först inskickad som uppfyllde QC-kriterierna

1 juli 2026

Första postat (Faktisk)

6 juli 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

25 augusti 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

23 augusti 2026

Senast verifierad

1 juli 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 26-VIC-0001

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera